Obicetrapib
As of the edition of 20 October 2026, Obicetrapib is a small molecule: in active development; acts on CETP.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2028
- Kind
- Small molecule
- Registered trials
- 26, 0 stopped early
- Disease areas
- Nutrition and metabolism; Heart and blood vessels; Inherited and neonatal; Mental health; Nervous system; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CETP | Cholesteryl ester transfer protein | P11597 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 8 | 1 | 0 |
| Phase 2 | 10 | 7 | 3 | 0 |
| Phase 3 | 7 | 3 | 4 | 0 |
| All trials | 26 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tanabe Pharma | Lead sponsor of trials | 2008 to now |
| Xention | Lead sponsor of trials | 2013 to now |
| NewAmsterdam Pharma | Lead sponsor of trials | 2021 to now |
| A. Menarini | Lead sponsor of trials | 2026 to now |